LAVA Therapeutics NV
NASDAQ:LVTX
Intrinsic Value
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. [ Read More ]
The intrinsic value of one
LVTX
stock under the Base Case scenario is
1.95
USD.
Compared to the current market price of 2.74 USD,
LAVA Therapeutics NV
is
Overvalued by 29%.
LAVA Therapeutics NV's market capitalization is 72m USD.
LVTX stock price is 2.74 USD.
LVTX stock (1.95 USD) is 29% less than its price (2.74 USD).
LVTX stock (1.99 USD) is 27% less than its price (2.74 USD). Open Relative Valuation
LVTX has upside potential of 153% compared to the average analyst price target.
Open Wall St Estimates
LVTX has positive Gross Profit for the last twelve months.
LVTX's Revenue has dropped by 65% over the past 12 months.
LVTX's long-term assets (102m USD) exceed its long-term liabilties (51m USD).
LVTX has negative Operating Income for the last twelve months.
LVTX has negative Net Income for the last twelve months.
LVTX's ROE (Return on Equity) for the past 12 months is negative and is equal to -61%.
LVTX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -1 063%.
LVTX has negative Free Cash Flow for the last twelve months.
LVTX's D/E (Debt to Equity) is very low and is equal to 0.11.
LVTX has negative three-year average ROE (Return on Equity): -59%. The company is not efficient at transforming stockholders' equity into net income.
LVTX has negative three-year average ROIC (Return on Invested Capital): -1 237%. The company is not efficient at using invested capital to generate operating income.
LVTX's short-term assets (99m USD) exceed its short-term liabilties (15m USD).
LVTX has negative Net Debt. This means that the company has more cash and short-term investments (96m USD) than debt (6m USD).
LVTX's Altman Z-Score is very low and is equal to -2.79.
Valuation Backtest
LAVA Therapeutics NV
Run backtest to discover the historical profit from buying and selling
LVTX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
LAVA Therapeutics NV
Balance Sheet Decomposition
LAVA Therapeutics NV
| Current Assets | 98.9m |
| Cash & Short-Term Investments | 95.6m |
| Receivables | 1.7m |
| Other Current Assets | 1.6m |
| Non-Current Assets | 2.8m |
| PP&E | 2.5m |
| Other Non-Current Assets | 319k |
| Current Liabilities | 14.9m |
| Accounts Payable | 4.4m |
| Accrued Liabilities | 4.8m |
| Short-Term Debt | 5.3m |
| Other Current Liabilities | 440k |
| Non-Current Liabilities | 35.6m |
| Long-Term Debt | 591k |
| Other Non-Current Liabilities | 35m |
Earnings Waterfall
LAVA Therapeutics NV
|
Revenue
|
6.8m
USD
|
|
Cost of Revenue
|
-3.5m
USD
|
|
Gross Profit
|
3.3m
USD
|
|
Operating Expenses
|
-46.5m
USD
|
|
Operating Income
|
-43.3m
USD
|
|
Other Expenses
|
1.3m
USD
|
|
Net Income
|
-42m
USD
|
Free Cash Flow Analysis
LAVA Therapeutics NV
LVTX Profitability Score
Profitability Due Diligence
LAVA Therapeutics NV's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
LAVA Therapeutics NV's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
LVTX Solvency Score
Solvency Due Diligence
LAVA Therapeutics NV's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Score
LAVA Therapeutics NV's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LVTX Price Targets Summary
LAVA Therapeutics NV
According to Wall Street analysts, the average 1-year price target for
LVTX
is 6.94 USD
with a low forecast of 5.05 USD and a high forecast of 11.55 USD.
Shareholder Return
LVTX Price
LAVA Therapeutics NV
| Average Annual Return | -49.04% |
| Standard Deviation of Annual Returns | 12.64% |
| Max Drawdown | -93% |
| Market Capitalization | 72m USD |
| Shares Outstanding | 26 289 100 |
| Percentage of Shares Shorted | 1.32% |
Company Profile
LAVA Therapeutics NV
Country
Industry
Market Cap
Dividend Yield
Description
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Contact
IPO
Employees
Officers
The intrinsic value of one
LVTX
stock under the Base Case scenario is
1.95
USD.
Compared to the current market price of 2.74 USD,
LAVA Therapeutics NV
is
Overvalued by 29%.
You don't have any saved screeners yet
